We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Prevention of Biofilm Formation Renders Bacteria Susceptible to Macrophage Attack

By HospiMedica staff writers
Posted on 17 Jul 2008
Microbiologists have used a recently patented antibiofilm enzyme to show that bacteria require both a leukotoxic agent and a surface polysaccharide to survive attack by immune system macrophages.

Biofilms are a major cause of a number of serious medical problems including chronic infections and medical device related infections. More...
They develop on surfaces such as catheters, prosthetic implants, teeth, lungs, and the urogenital tract. Biofilms are pervasive, costly to deal with, and approximately 80% of all human bacterial infections involve biofilms.

Investigators from the University of Medicine and Dentistry (Newark, NJ, USA) worked with monolayer cultures of the human macrophage cell line THP-1. The cultures were infected with either wild type cultures of the bacterium Aggregatibacter actinomycetemcomitans (A.a) or with A.a mutants lacking either leukotoxin, a secreted lipoprotein that kills human polymorphonuclear leukocytes and macrophages, or poly-N-acetylglucosamine (PGA), a surface polysaccharide that mediates intercellular adhesion, biofilm formation, and detergent resistance.

In some experiments the bacteria were treated with Kane Biotech, Inc's (Winnipeg, MB, CA) patented antibiofilm enzyme Dispersin B, which is capable of both inhibiting and dispersing bacterial biofilms.

Results published in the June 5, 2008, online edition of the journal Microbial Pathogenesis revealed that pretreatment of wild-type A.a cells with the PGA-hydrolyzing enzyme dispersin B rendered them sensitive to killing by THP-1 cells leading to the conclusion that both leukotoxin and PGA were necessary for evasion of macrophage killing by A.a.

"Our studies showed that the pretreatment of biofilm-embedded A.a cells with DispersinB removes the biofilm and renders the cells sensitive to killing by the body's macrophages,” said senior author Dr. Jeffery Kaplan, professor of oral biology at the University of Medicine and Dentistry.

"The findings of Dr. Kaplan's group suggest that when DispersinB is used in products such as wound gels and device coatings, either in combination with an antimicrobial or alone, it makes biofilm-embedded bacterial pathogens susceptible to killing by both antimicrobials and macrophages or by our body's macrophages alone,” said Dr. Sri Madhyastha, CSO of Kane Biotech.


Related Links:
University of Medicine and Dentistry
Kane Biotech

Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Floor‑Mounted Digital X‑Ray System
MasteRad MX30+
Absorbable Monofilament Mesh
Phasix Mesh
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The fiber in the brain implant is less than half a millimeter thick (Photo courtesy of Peter Aagaard Brixen)

Brain Implant Records Neural Signals and Delivers Precise Medication

Neurological diseases such as epilepsy involve complex interactions across multiple layers of the brain, yet current implants can typically stimulate or record activity from only a single point.... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.